Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cocrystal Pharma ( (COCP) ) has provided an announcement.
Cocrystal Pharma announced an extension of enrollment in its Phase 2a human challenge study for the investigational oral influenza PB2 inhibitor, CDI-42344, due to low influenza infection rates among participants. Despite these challenges, the company remains optimistic about the drug’s potential as a leading antiviral treatment for influenza, citing its safety profile and unique mechanism of action. The company is working on a protocol amendment to ensure sufficient infection rates, which is crucial for evaluating the drug’s antiviral effectiveness.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that focuses on discovering and developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. Utilizing unique structure-based technologies and Nobel Prize-winning expertise, the company aims to create first- and best-in-class antiviral drugs.
YTD Price Performance: 88.73%
Average Trading Volume: 30,560
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $33.06M
See more insights into COCP stock on TipRanks’ Stock Analysis page.
